HSK401 (Bevacizumab Biosimilar)
Non-small Cell Lung Cancer, Colorectal Cancer
Phase IIINDA Submitted
Key Facts
Indication
Non-small Cell Lung Cancer, Colorectal Cancer
Phase
Phase III
Status
NDA Submitted
Company
About Haisco Pharmaceutical Group
Haisco Pharmaceutical Group's mission is to develop and deliver innovative, high-quality medicines to address unmet medical needs in China and globally. The company has achieved significant scale, becoming one of China's top pharmaceutical firms by market value, through a successful 'generic-to-innovative' transition strategy. Its core strategy is built on vertical integration, using stable cash flows from its generics and established drug portfolio to fund R&D in high-growth therapeutic areas, while expanding its commercial reach across China's vast healthcare market.
View full company profile